PUBLISHER: GlobalData | PRODUCT CODE: 1482984
PUBLISHER: GlobalData | PRODUCT CODE: 1482984
Breast cancer (International Classification of Diseases, 10th Revision [ICD-10] codes C50.0-50.9) is a malignant tumor that originates in the breast tissue. Breast cancer cells begin inside the milk ducts of the breast. The earliest form (in situ) is not life-threatening and can be detected in early stages. The most common type of non-invasive (stage 0) types of breast cancer is called ductal carcinoma in situ (DCIS) (American Cancer Society, 2022; World Health Organization, 2024). DCIS refers to abnormal cells that are present in the breast ducts but have not invaded through duct walls into the surrounding breast tissue (American Cancer Society, 2022). Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system (American Cancer Society, 2022).
According to the World Health Organization (WHO), breast cancer is the most diagnosed cancer in women and is the leading cause of cancer death in women globally (International Agency for Research on Cancer, 2020; World Health Organization, 2022). Breast cancer accounts for 25.20% of all incident cases of female cancers, making the disease exceedingly prevalent (International Agency for Research on Cancer, 2014). Risk factors for breast cancer include prolonged exposure to endogenous and exogenous sex hormones; gene mutations; a family history of breast cancer; overweight and obesity; physical inactivity; a sedentary lifestyle; high alcohol consumption; early age at menarche (younger than 12 years); late age at menopause (older than 55 years); and clinical factors, such as biopsy-confirmed atypical hyperplasia and having a high breast tissue and bone density (International Agency for Research on Cancer, 2020; American Cancer Society, 2022). Breast cancer is classified based on human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status (American Cancer Society, 2022). This report explores HER2-positive (HER2+) breast cancer, namely, HER2+/HR+ and HER2+/HR- breast cancer.
In the 8MM, the diagnosed incident cases of invasive HER2+/HR+ breast cancer are expected to increase from 107,352 cases in 2023 to 123,580 cases in 2033, at an annual growth rate (AGR) of 1.51%. In 2033, urban China will have the highest number of diagnosed incident cases of invasive HER2+/HR+ breast cancer in the 8MM, with 52,693 diagnosed incident cases, whereas Spain will have the fewest diagnosed incident cases with 4,157 cases. In the 8MM, the diagnosed incident cases of invasive HER2+/HR- breast cancer are expected to increase from 59,598 cases in 2023 to 68,846 cases in 2033, at an AGR of 1.55%. In 2033, urban China will have the highest number of diagnosed incident cases of invasive HER2+/HR- breast cancer in the 8MM, with 33,589 diagnosed incident cases, whereas Spain will have the fewest diagnosed incident cases with 2,100 cases.
In the 8MM, the five-year diagnosed prevalent cases of invasive HER2+/HR+ breast cancer are expected to increase from 490,025 cases in 2023 to 564,254 cases in 2033, at an AGR of 1.51%. In the 8MM, the five-year diagnosed prevalent cases of invasive HER2+/HR- breast cancer are expected to increase from 258,971 cases in 2023 to 299,126 cases in 2033, at an AGR of 1.55%. GlobalData epidemiologists attribute the increase in the diagnosed incident cases and five-year diagnosed prevalent cases to a certain extent with the moderately rising trend in the incidence rates in the 8MM, combined with underlying demographic changes in the respective markets.
The HER2-Positive Breast Cancer epidemiology series will allow you to -